Koutsoumparis et al. treated SCAP with erythropoietin (rhEPOa) and found that CD31, CDH5 and VEGFR2 were upregulated and MMP2-pathway was activated [33]. The gene discussed is EPO; the disease is syringocystadenoma papilliferum.